Executive summary: United States Drug Patent US 12,594,244 is a formulation-and-performance estate centered on specific fixed-dose tablet compositions containing (i) a claimed “compound of Formula I” or “compound of Formula II” plus tenofovir alafenamide (or tenofovir alafenamide hemifumarate) and emtricitabine, and (ii) dissolution/release performance measured under a defined USP apparatus II, fasted SIF pH 6.5 conditions, plus (iii) excipients/absence or presence limitations (notably lactose/crospovidone/sodium stearyl fumarate exclusions and inclusion of croscarmellose sodium, magnesium stearate, microcrystalline cellulose). The independent scope is heavily constrained by (a) wt% ranges, (b) salt identity for TAF where specified, (c) dissolution thresholds and timepoints, and (d) tablet weight range and coated-tablet status. Without the actual issued specification context (definitions of Formula I/II), the landscape can be mapped only at the level of these claim-structural constraints; no complete, jurisdiction-by-jurisdiction freedom-to-operate or validity analysis is possible from claim text alone.
What patents protect US 12,594,244 tablet formulations with tenofovir alafenamide hemifumarate and emtricitabine?
How broad are the composition claims 1–5 versus composition claims 9?
Core claim approach: The estate uses two layers of composition scope.
Claim 1: Formula I + TAF + emtricitabine wt% ranges
Claim 1 requires a tablet with:
- 6.5–11.0% w/w of a compound of Formula I (or pharmaceutically acceptable salt)
- 3.0–4.5% w/w tenofovir alafenamide (or salt)
- 25–30% w/w emtricitabine (or salt)
This is broad on:
- the identity of the Formula I compound (not provided here)
- tenofovir alafenamide being flexible (salt or free base)
It is narrow on:
- the wt% bands (hard quantitative limits)
- the requirement that it is a tablet with the three active components in those proportions
Claim 2: Formula II + TAF hemifumarate + emtricitabine
Claim 2 narrows the composition by fixing the salt form:
- 7.0–11.0% w/w of compound of Formula II
- 3.5–4.1% w/w tenofovir alafenamide hemifumarate
- 25–30% w/w emtricitabine
Compared with claim 1, the salt constraint and slightly shifted TAF wt% band make claim 2 easier to design around if a competitor uses different salt form or adjusts within allowable processing tolerances.
Claim 9: “tight” multi-excipient quantitative formulation
Claim 9 locks the tablet to a structured window:
- 6.4–8.5% w/w Formula II
- 25–32% w/w emtricitabine
- 3.5–4.5% w/w TAF hemifumarate
- 46–57% w/w microcrystalline cellulose
- 5.9–8.5% w/w croscarmellose sodium
- 1.0–2.0% w/w magnesium stearate
This is significantly narrower than claim 2 because it adds both:
- specific qualitative excipient presence (microcrystalline cellulose, croscarmellose sodium, magnesium stearate)
- explicit excipient wt% ranges
Design-around implication: A generic or challenger can be attacked for infringement if it matches the compound wt% bands, AND the dissolution thresholds, AND the excipient set if targeting claims 9/10 or dependent excipient claims.
What do claims 3–5 do to the excipient scope?
Claims 3–5 are classic exclusion/inclusion gatekeepers.
- Claim 3 (from claim 1): tablet does not contain lactose, crospovidone, or sodium stearyl fumarate.
- Claim 4 (from claim 1): tablet further comprises croscarmellose sodium or magnesium stearate.
- Claim 5 (from claim 1): tablet further comprises croscarmellose sodium, magnesium stearate, or microcrystalline cellulose.
These claims matter because formulation substitutes can change:
- compressibility and tablet hardness
- disintegration and dissolution kinetics
- impurity profiles
A competitor using lactose or crospovidone can avoid claim 3, but may still fall into other dependent claims that require other excipients.
Does the patent cover only uncoated tablets or also coated tablets?
- Claim 13: coated tablet (from claim 1)
- Claim 10: further comprises a film coating (from claim 9)
- Claim 20: coated tablet (from claim 2)
This indicates the estate is not limited to uncoated tablets. Coating can be an additional design variable but is not an escape if the rest of the composition and dissolution claims are met.
What is the tablet weight limitation and why it matters?
- Claims 14 and 21 and 28: total tablet weight between 250 and 750 mg.
This can be used as a computational check for potential infringement: if the competitor’s final tablet weight falls outside that range, claims with this limitation are avoided.
What dissolution and release performance limitations define claim scope in US 12,594,244?
Which claims impose USP apparatus II release thresholds?
The key performance limitations appear in:
- Claims 6–8 (Formula I; dependent on claim 1)
- Claims 22–24 (Formula II; dependent on claim 22)
- Claims 25–27 (Formula II; dependent on claim 25)
Claim 6: Formula I release in fasted SIF pH 6.5
Requires:
- release of at least ~50% of Formula I compound (or salt)
- in about 20 minutes
- using USP apparatus II
- 333 mL fasted simulated intestinal fluid, pH 6.5, 37°C, paddle 100 rpm
Claim 7: at least 60% in about 20 minutes
Claim 8: at least 70% in about 60 minutes
The Formula II performance track is structurally parallel:
- Claim 22: at least ~50% of Formula II in 20 min (USP II, same medium and conditions)
- Claim 23: at least 60% in 20 min
- Claim 24: at least 70% in 60 min
And the claim 25–27 set repeats those release thresholds while further tethered to claim 9 composition constraints.
How does the performance requirement affect enforcement strategy?
For litigation, performance claims shift the dispute toward:
- comparator lab testing under specified apparatus and media
- batch-to-batch reproducibility
- dissolution method equivalency arguments
Because the claims specify USP apparatus II conditions, a competitor can aim to show:
- its product falls below a threshold (e.g., 58% instead of “at least 60%”)
- it does not match the formulation constraints that enable the release test to be measured against the claimed active (“compound of Formula I/II”)
What excipient absence and inclusion features are explicitly claimed?
Are specific excipients excluded?
Yes:
- lactose
- crospovidone
- sodium stearyl fumarate
This is only explicitly stated in the context of the claims derived from claim 1 and claim 2 (claims 3 and 15).
Which excipients are explicitly included in dependent form?
- croscarmellose sodium
- magnesium stearate
- microcrystalline cellulose
Claims 4, 5, 11, 12, 16–19, 17, and 19 indicate multiple dependent combinations.
In practice, the narrowest formulations are those that satisfy claim 9 excipient wt% ranges (microcrystalline cellulose 46–57%, croscarmellose sodium 5.9–8.5%, magnesium stearate 1.0–2.0%).
What is the legal scope for infringement risk: literal infringement vs design-around?
Where is the tightest literal infringement path?
The tightest path is through claim 9 plus claim 10 (film coating) plus claim 25–27 (release thresholds for Formula II), with possible additional constraints from coating and tablet weight.
A product is at highest literal risk if it:
- Uses Formula II compound in 6.4–8.5% w/w
- Has emtricitabine 25–32% w/w
- Uses tenofovir alafenamide hemifumarate 3.5–4.5% w/w
- Uses microcrystalline cellulose 46–57% w/w
- Uses croscarmellose sodium 5.9–8.5% w/w
- Uses magnesium stearate 1.0–2.0% w/w
- Has coating status (if pursued via dependent claims)
- Meets USP II dissolution thresholds exactly defined
Where can competitors design around more easily?
- Salt form switch: claim 2 and claim 9 lock TAF hemifumarate. If a competitor uses a different acceptable salt form or adjusts to avoid those exact hemifumarate wt% windows, it can avoid those dependents. Claim 1 is broader because it allows tenofovir alafenamide more generally.
- Excipient substitution: claim 3 excludes lactose, crospovidone, sodium stearyl fumarate. Introducing one of these can avoid that exclusion-dependent claim. However, it may create new risk against other dependent claims that require certain excipients or the absence list is only partial.
- Quant window shifts: small shifts at the boundary (e.g., moving Formula II compound from 6.41% to 6.39% w/w) can avoid claim 9 while leaving claim 2 still possible (7.0–11.0% for claim 2). That produces a multi-claim matrix rather than a single answer.
- Dissolution performance: the estate is vulnerable to controlled reformulation aimed at missing one of the timepoint thresholds (20 min or 60 min). The claims are not “about any release profile”; they tie release to specified criteria.
What adjacent patent claims are likely in the same estate and how do they interact?
Which claim types are present here, indicating the likely estate structure?
Even without the specification, claim structure indicates these likely neighboring families:
- composition of matter/formulation claims for fixed-dose combination tablets
- salt form and ratio claims (TAF hemifumarate specifically)
- excipients exclusions/inclusions (lactose and superdisintegrant exclusions; MCC and croscarmellose sodium inclusion)
- dissolution/disintegration method claims using USP apparatus II under fasted intestinal conditions
From an enforcement standpoint, such estates often have multiple layers:
- independent composition claims (broad wt%)
- dependent narrow composition claims (including excipient wt% and coated status)
- dependent performance claims (dissolution thresholds)
This can support both:
- broad pleadings against complex product matches
- secondary coverage if only performance or only excipient structure matches
What Orange Book status does US 12,594,244 likely influence?
No Orange Book listing can be derived from the claim text you provided. US 12,594,244 is a patent number, not an Orange Book record. Orange Book status depends on:
- the listed NDA/ANDA
- which drug product(s) the patent was submitted against
- whether it is listed as a method-of-use or formulation patent under relevant regulatory descriptions
Because that mapping is not contained in your input, no definitive Orange Book status can be provided.
How many generic entry risks exist against this estate, and what are the key technical failure points?
Risk scenarios
Three main risk paths appear from the claim architecture:
-
Full match generics (high risk):
- replicate fixed-dose ratios and excipient windows
- meet dissolution thresholds under the same USP II method
-
Ratio-match but excipient-shift generics (medium risk):
- avoid claim 9 excipient wt% windows but still risk claims 1–2 and dissolution claims if formulation is close and meets thresholds
-
Dissolution-avoidance generics (case-specific risk):
- use different excipient set to slow release below a claimed threshold
- ensure performance does not satisfy “at least 50%/60%/70%” at the specified timepoints
Fasted intestinal fluid pH 6.5 USP II: the testing chokepoint
Claims tie release to:
- fasted simulated intestinal fluid pH 6.5
- 333 mL
- 37°C
- 100 rpm
Any generic development that does not control these test conditions and produces a substantially different dissolution profile is likely to be litigated on method adherence and quantitative outcomes.
What is the claim-by-claim scope matrix for competitive evaluation?
Infringement matrix (condensed)
| Claim |
Drug actives |
Key wt% constraints |
Salt constraints |
Excipients (explicit) |
Performance constraint |
| 1 |
Formula I + TAF + FTC |
Formula I 6.5–11.0%; TAF 3.0–4.5%; FTC 25–30% |
TAF general (salt ok) |
Exclusion not required; dependents cover exclusions/inclusions |
None in claim 1 |
| 2 |
Formula II + TAF hemifumarate + FTC |
Formula II 7.0–11.0%; TAF hemifumarate 3.5–4.1%; FTC 25–30% |
TAF as hemifumarate |
None in claim 2 |
None in claim 2 |
| 3 |
From claim 1 |
Same as claim 1 |
Same as claim 1 |
No lactose, no crospovidone, no sodium stearyl fumarate |
None |
| 4–5 |
From claim 1 |
Same as claim 1 |
Same as claim 1 |
Inclusion variants of croscarmellose sodium / magnesium stearate / microcrystalline cellulose |
None |
| 6–8 |
From claim 1 |
Same as claim 1 |
Same as claim 1 |
None in independent recitation |
USP II fasted SIF pH 6.5: ≥50% at 20 min; ≥60% at 20 min; ≥70% at 60 min (Formula I) |
| 9 |
Formula II + TAF hemifumarate + FTC + excipients |
Formula II 6.4–8.5%; FTC 25–32%; TAF 3.5–4.5%; MCC 46–57%; CCS 5.9–8.5%; MgSt 1.0–2.0% |
TAF as hemifumarate |
MCC, croscarmellose sodium, magnesium stearate with exact wt% windows |
None in claim 9 |
| 10 |
From claim 9 |
Same as claim 9 |
Same as claim 9 |
film coating required |
None |
| 13 |
From claim 1 |
Same as claim 1 |
Same as claim 1 |
coated tablet |
None |
| 14 |
From claim 1 |
Same as claim 1 |
Same as claim 1 |
tablet wt 250–750 mg |
None |
| 15 |
From claim 2 |
Same as claim 2 |
Same as claim 2 |
No lactose, no crospovidone, no sodium stearyl fumarate |
None |
| 17–19 |
From claim 1 or claim 2 |
Same |
Same |
excipient combinations |
None |
| 20–21 |
From claim 2 |
Same |
Same |
coated tablet; tablet wt 250–750 mg |
None |
| 22–24 |
From claim 2 |
Same as claim 2 |
Same as claim 2 |
None |
USP II fasted SIF pH 6.5: ≥50% at 20 min; ≥60% at 20 min; ≥70% at 60 min (Formula II) |
| 25–27 |
From claim 9 |
Same as claim 9 |
Same as claim 9 |
none in recitation |
performance thresholds for Formula II (USP II conditions) |
| 28 |
From claim 9 |
Same as claim 9 |
Same as claim 9 |
tablet wt 250–750 mg |
None |
| 29 |
Method of therapeutic treatment |
Administers composition of claim 9 range set |
TAF hemifumarate fixed |
composition excipient windows in claim 9 |
None; ties treatment to the tablet composition |
What method-of-use scope exists in claim 29 for HIV infection treatment?
Claim 29 covers:
- therapeutic treatment of HIV infection
- administering a subject a tablet matching the composition windows of claim 9:
- Formula II 6.4–8.5% w/w
- emtricitabine 25–32% w/w
- tenofovir alafenamide hemifumarate 3.5–4.5% w/w
- MCC 46–57% w/w
- croscarmellose sodium 5.9–8.5% w/w
- magnesium stearate 1.0–2.0% w/w
This is a typical “use follows product” type claim. If a competitor product matches claim 9 composition and is prescribed for HIV, the method claim is likely to be asserted as derivative risk.
Key takeaways
- US 12,594,244 is a fixed-dose tablet formulation patent with tight quantitative composition windows and explicit dissolution performance criteria under USP apparatus II in fasted SIF pH 6.5.
- The highest coverage risk is for products that match claim 9 excipient wt% ranges (MCC, croscarmellose sodium, magnesium stearate) plus meet claim 25–27 dissolution thresholds for Formula II.
- The estate supports enforcement on both composition and performance. Design-arounds are most plausible via:
- shifting out of wt% bands
- switching salt form away from TAF hemifumarate where claims require it
- changing excipient set to trigger the lactose/crospovidone/sodium stearyl fumarate exclusion-dependent claims
- engineering dissolution profile to miss “at least” release thresholds at the specified timepoints.
- Claim text alone does not identify the Orange Book NDA/ANDA mapping, the full family/patent landscape, or the exact identity of “Formula I/II,” so those determinations cannot be completed from the provided material.
FAQs
-
How do the USP apparatus II parameters in US 12,594,244 shape generic testing obligations?
They lock the dissolution conditions (333 mL fasted SIF pH 6.5, 37°C, 100 rpm) and create a direct infringement assay for the “at least 50%/60%/70%” thresholds at 20 and 60 minutes.
-
Does the patent require tenofovir alafenamide specifically as hemifumarate?
Not in claim 1, but yes in claim 2 and all claim 9-based dependents and performance claims (TAF hemifumarate).
-
Which claim is most relevant for a full product copycat risk assessment?
Claim 9, because it includes the narrowest multi-component quantitative excipient windows and anchors the strongest dependent dissolution and method-of-use coverage.
-
Can adding lactose or crospovidone avoid infringement?
It can avoid lactose/crospovidone/sodium stearyl fumarate exclusion-dependent claims (claims 3 and 15), but it does not necessarily avoid other claims not tied to that exclusion.
-
What is the practical role of tablet weight (250–750 mg) in enforcement?
It limits dependent coverage (claims 14, 21, 28). A competitor outside that range can reduce risk for those specific dependents, but not necessarily for claims without the tablet weight limitation.
References
- US 12,594,244 (United States Patent).
